AAPS PharmSciTech

, Volume 4, Issue 3, pp 24–35

Preparation and characterization of novel coenzyme Q10 nanoparticles engineered from microemulsion precursors

  • Cheng-Hsuan Hsu
  • Zhengrong Cui
  • Russell J. Mumper
  • Michael Jay
Article

Abstract

The purpose of these studies was to prepare and characterize nanoparticles into which Coenzyme Q10 (CoQ10) had been incorporated (CoQ10-NPs) using a simple and potentially scalable method. CoQ10-NPs were prepared by cooling warm microemulsion precursors composed of emulsifying wax, CoQ10, Brij 78, and/or Tween 20. The nanoparticles were lyophilized, and the stability of CoQ10-NPs in both lyophilized form and aqueous suspension was monitored over 7 days. The release of CoQ10 from the nanoparticles was investigated at 37°C. Finally, an in vitro study of the uptake of CoQ10-NPs by mouse macrophage, J774A.1, was completed. The incorporation efficiency of CoQ10 was approximately 74%±5%. Differential Scanning Calorimetry (DSC) showed that the nanoparticle was not a physical mixture of its individual components. The size of the nanoparticles increased over time if stored in aqueous suspension. However, enhanced stability was observed when the nanoparticles were stored at 4°C. Storage in lyophilized form demonstrated the highest stability. The in vitro release profile of CoQ10 from the nanoparticles showed an initial period of rapid release in the first 9 hours followed by a period of slower and extended release. The uptake of CoQ10-NPs by the J774A.1 cells was over 4-fold higher than that of the CoQ10-free nanoparticles (P<.05). In conclusion, CoQ10-NPs with potential application for oral CoQ10 delivery were engineered readily from microemulsion precursors.

Keywords

Coenzyme Q10 nanoparticles microemulsion stability cell uptake 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Frei B, Kim MC, Ames BN. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci U S A. 1990;87:4879–4883.CrossRefGoogle Scholar
  2. 2.
    Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquin one). Clin Investig. 1993;71(suppl 8):S116-S123.Google Scholar
  3. 3.
    Casey AC, Bliznakov EG. Effect and structure-activity relationship of coenzymes Q on the phagocytic rate of rats. Chem Biol Interact. 1972;16:1504–1510.Google Scholar
  4. 4.
    Siekmann B, Westesen K. Preparation and physicochemical characterization of aqueous dispersions of coenzyme Q10 nanoparticles. Pharm Res. 1995;12:201–208.CrossRefGoogle Scholar
  5. 5.
    Greenberg S, Frishman WH. Coenzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol. 1990;30:590–608.Google Scholar
  6. 6.
    Kishi H, Kanamori N, Niraoka E, Okamato T, Kishi T. Metabolism of exogenous coenzyme Q10 in vivo and bioavailability of coenzyme Q10 preparations in Japan. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 4. Amsterdam: Elsevier Science; 1984: 131–142.Google Scholar
  7. 7.
    Weis M, Mortensen SA, Rassing MR, Moller-Sonnergaard J, Poulsen G, Rasmussen SN. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med. 1994;15(suppl):S273-S280.CrossRefGoogle Scholar
  8. 8.
    Takeuchi H, Sasaki H, Niwa T, Hino T, Kawashima Y, Uesugi K, Ozawa H. Improvement of photostability of ubidecarenone in the formulation of a novel powdered dosage form termed redispersible dry emulsion. Int J Pharm. 1992;86:25–33.CrossRefGoogle Scholar
  9. 9.
    Lutka A, Pawlaczyk J. Inclusion complexation of coenzyme Q10 with cyclodextrins. Acta Pol Pharm. 1995;52:379–386.Google Scholar
  10. 10.
    Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm. 2001;212:233–246.CrossRefGoogle Scholar
  11. 11.
    Maincent P, LeVerge R, Sado P, Couvreur P, Devissaguet JP. Disposition kinetics of vicamine loaded polyalkylcyanoacrylate nanoparticles. J Pharm Sci. 1986;75:955–958.CrossRefGoogle Scholar
  12. 12.
    El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm. 2002;249:101–108.CrossRefGoogle Scholar
  13. 13.
    Mathiowitz E, Jacob JS, Jong YS, Carino GP, Chickering DE, Chaturvedi P, Santos CA, Vijayaraghavan K, Montgomery S, Bassett M, Morrell C. Biologically erodible microspheres as potential oral drug delivery systems. Nature. 1997;386:410–414.CrossRefGoogle Scholar
  14. 14.
    Bunjes H, Drechsler M, Koch MH, Westesen K. Incorporation of the model drug ubidecarenone into solid lipid nanoparticels. Pharm Res. 2001;18:278–293.CrossRefGoogle Scholar
  15. 15.
    Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 1996;13:1838–1845.CrossRefGoogle Scholar
  16. 16.
    Thünemann AF, General S. Nanoparticles of polyelectrolytefatty acid complex: carriers for Q10 and triiodothyronine. J Control Release. 2001;75:237–247.CrossRefGoogle Scholar
  17. 17.
    Kwon SS, Nam YS, Lee JS, Ku BS, Han SH, Lee JY, Chang IS. Preparation and characterization of coenzyme Q10-loaded PMMA nanoparticles by a new emulsification process based on microfluidization. Colloids and Surfaces A. 2002;210:95–104.CrossRefGoogle Scholar
  18. 18.
    Cui Z, Mumper RJ. Genetic immunization using nanoparticles engineering from microemulsion precursors. Pharm Res. 2002;19:939–946.CrossRefGoogle Scholar
  19. 19.
    Cui Z, Mumper RJ. Plasmid DNA-entrapped nanoparticles engineered from microemulsion precursors: in vitro and in vivo evaluation. Bioconjug Chem. 2002;13:1319–1327.CrossRefGoogle Scholar
  20. 20.
    Cui Z, Mumper RJ. Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses. J Pharm Pharmacol. 2002;54:1195–1203.CrossRefGoogle Scholar
  21. 21.
    Cui Z, Hsu C-H, Mumper RJ. Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev Ind Pharm. 2003;29:689–700.CrossRefGoogle Scholar
  22. 22.
    Hsu C-H, Cui Z, Jay M. Nanoparticles engineered from microemulsion precursors for coenzyme Q10 (CoQ10) delivery: preparation and characterization [abstract]. AAPS Pharm Sci. 2002;4(4):W5120.Google Scholar
  23. 23.
    Makabi-Panzu B, Sprott GD, Patel GB. Coenzyme Q10 in vesicles composed of archaeal ether lipids or conventional lipids enhances the immuno-adjuvanticity to encapsulated protein. Vaccine. 1998;16:1504–1510.CrossRefGoogle Scholar
  24. 24.
    Nazzal S, Zaghloul AA, Reddy IK, Khan MA. Analysis of ubidecarenone (CoQ10) aqueous simple using reversed phase liquid chromatography. Pharmazie. 2001;56:394–396.Google Scholar
  25. 25.
    Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery II. Drug incorporation and physical characterization. J Microencapsul. 1999;16:205–213.CrossRefGoogle Scholar
  26. 26.
    Martin A, Swarbrick J, Cammarata A. Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences. 3rd ed. Philadelphia, PA: Lea & Febiger, 1983:452–454.Google Scholar
  27. 27.
    Schwarz C, Mehnert W. Freeze-drying of drug-free and drugloaded solid lipid nanoparticles (SLN). Int J Pharm. 1997;157:171–179.CrossRefGoogle Scholar
  28. 28.
    Chen DB, Yang TZ, Lu WL, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull. 2001;49:1444–1447.CrossRefGoogle Scholar
  29. 29.
    Doebbler GF. Cryoprotective compounds. Cryobiology. 1966;3:2–11.CrossRefGoogle Scholar
  30. 30.
    Ford AW, Dawson PJ. The effect of carbohydrate additives in the freeze-drying of alkaline phosphatase. J Pharm Pharmacol. 1993;45:86–93.Google Scholar
  31. 31.
    Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177.CrossRefGoogle Scholar
  32. 32.
    Saiki I, Tokushima Y, Nishimura K, Azuma I. Macrophage activation with ubiquinones and their related compounds in mice. Int J Vitam Nutr Res. 1983;53:312–320.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2003

Authors and Affiliations

  • Cheng-Hsuan Hsu
    • 1
  • Zhengrong Cui
    • 1
  • Russell J. Mumper
    • 1
  • Michael Jay
    • 1
  1. 1.Division of Pharmaceutical Sciences, College of PharmacyUniversity of KentuckyLexington

Personalised recommendations